LoginSignup
Incyte logo

Incyte Stock

StockStock
ISIN: US45337C1027
Ticker: INCY
US45337C1027
INCY

Price

Frequently asked questions

What is Incyte's market capitalization?

The market capitalization of Incyte is $14.24B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Incyte's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Incyte is 528.26. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Incyte?

Incyte's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.14. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Incyte's stock?

Currently, 22 analysts cover Incyte's stock, with a consensus target price of $71.44. Analyst ratings provide insights into the stock's expected performance.

What is Incyte's revenue over the trailing twelve months?

Over the trailing twelve months, Incyte reported a revenue of $4.08B.

What is the EBITDA for Incyte?

Incyte's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $107.68M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Incyte?

Incyte has a free cash flow of $30.70M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Incyte's stock?

The 5-year beta for Incyte is 0.73. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Incyte have, and what sector and industry does it belong to?

Incyte employs approximately 2,524 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Incyte's shares?

The free float of Incyte is 188.68M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $14.24B

5Y beta

 0.73

EPS (TTM)

 $0.14

Free Float

 188.68M

P/E ratio (TTM)

 528.26

Revenue (TTM)

 $4.08B

EBITDA (TTM)

 $107.68M

Free Cashflow (TTM)

 $30.70M

Pricing

52W span
$50.35$74.60

Analyst Ratings

The price target is $71.44 and the stock is covered by 22 analysts.

Buy

10

Hold

11

Sell

1

Information

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.

2,524

Biotechnology & Drugs

Health Care

Identifier

ISIN

US45337C1027

Primary Ticker

INCY

Knockouts

Join the conversation
Sign upLogin